Zithromax FDA warning: Increased risk of cancer relapse with long-term use after Donor Stem Cell Transplant

The Food and Drug Administration (FDA) issued a warning Friday concerning the long-term use of azithromycin (Zithromax, Zmax) for prophylaxis of bronchiolitis obliterans syndrome to patients who undergo donor stem cell transplants because of the increased potential for cancer relapse and death. Results of a clinical trial found an increased rate of relapse in cancers affecting the ["]

The post Zithromax FDA warning: Increased risk of cancer relapse with long-term use after Donor Stem Cell Transplant appeared first on Outbreak News Today.